Ding Wei, Liu Libin, Hu Renming, Xu Manyin, Chen Jialun
Shanghai Institute of Endocrinology, Department of Endocrinology, Ruijin Hospital, Shanghai Second Medical University, Shanghai 200025, China.
Chin Med J (Engl). 2002 Jul;115(7):979-82.
To report the clinical characteristics, biochemical profiles, diagnosis and treatment of one Chinese pedigree with glucocorticoid-remediable aldosteronism (GRA) and to study its molecular mechanism.
Plasma and urinary aldosterone, cortisol and plasma renin activities were dynamically tested and diagnostic therapy with dexamethasone was undergone in 3 affected subjects. Long-distance PCR as well as DNA sequencing were applied to detect the fusion gene in this pedigree.
In this GRA pedigree, there were 4 affected subjects who had hypertension, hypokalemia and low basic and provoked renin activity. Three patients were given dexamethasone treatment, and had a significant decrease in plasma aldosterone concentrations (PACs) (from 192 +/- 9 ng/L to 87 +/- 7ng/L, P < 0.05) after 5 days. Among them, one patient (II -3) responded quite satisfactorily to the therapy, with serum K(+) rising from baseline value of 2.5 to 2.9, 3.8 and 4.15 mEq/L on the 10th, 28th and 35th days after treatment respectively. Three weeks later, his blood pressure decreased from its original level of 146.3 +/- 1 0.7/94.6 +/- 5.3 mm Hg to 138.3 +/- 3.1/87.3 +/- 6.1 mm Hg (P < 0.05). The other 2 members (III -2 and III -4) showed modest improvement although their PACs decreased significantly. Using long-distance PCR, we found a 3.9 kb band in all 4 affected individuals, which was absent in 5 unaffected members from this pedigree or 8 patients with aldosterone-producing adenoma (APA) or idiopathic hyperaldosteronism (IHA). By DNA sequence analysis, we found that the breakpoint of "unequal crossing-over" is both within intron 2 of the 11beta-hydroxylase gene (CYP11B1) and the aldosterone synthase gene (CYP11B2).
The excess of mineralocorticoid in patients with GRA can be inhibited by exogenous glucocorticoids. The fusion gene resulting from unequal crossing-over between the 11beta-hydroxylase gene and the aldosterone synthase gene is the pathogenesis of this Chinese GRA pedigree.
报告一个中国糖皮质激素可治性醛固酮增多症(GRA)家系的临床特征、生化指标、诊断及治疗情况,并研究其分子机制。
对3例受累患者动态检测血浆和尿醛固酮、皮质醇及血浆肾素活性,并进行地塞米松诊断性治疗。应用长距离PCR及DNA测序检测该家系中的融合基因。
在这个GRA家系中,有4例受累患者,均有高血压、低钾血症,基础及激发肾素活性降低。3例患者接受地塞米松治疗,5天后血浆醛固酮浓度(PACs)显著下降(从192±9 ng/L降至87±7 ng/L,P<0.05)。其中1例患者(II-3)治疗反应良好,治疗后第10、28和35天血清钾分别从基线值2.5升至2.9、3.8和4.15 mEq/L。3周后,其血压从原来的146.3±10.7/94.6±5.3 mmHg降至138.3±3.1/87.3±6.1 mmHg(P<0.05)。另外2名成员(III-2和III-4)虽然PACs显著下降,但改善程度一般。通过长距离PCR,我们在所有4例受累个体中发现一条3.9 kb的条带,而在该家系5例未受累成员、8例醛固酮瘤(APA)或特发性醛固酮增多症(IHA)患者中未发现。通过DNA序列分析,我们发现“不等交换”的断点位于11β-羟化酶基因(CYP11B1)和醛固酮合成酶基因(CYP11B2)的第2内含子内。
外源性糖皮质激素可抑制GRA患者过多的盐皮质激素。11β-羟化酶基因与醛固酮合成酶基因之间不等交换产生的融合基因是这个中国GRA家系的发病机制。